BioCancell Therapeutics Inc. (BICL) closed little changed after earlier advancing to the highest intraday level in more than nine months as it successfully completing a clinical trial of its BC-819 drug to treat pancreatic cancer.

The shares rose less than 0.1 percent to 3.94 shekels at the 4:30 p.m. close in Tel Aviv. They gained as much as 12 percent to 4.40 shekels intraday. The stock has increased 62 percent this year, giving the Jerusalem-based company a market value of 81.4 million shekels ($22.4 million).

The Phase I/IIa trial was successful in meeting its targets, which were the safety and initial effectiveness of the drug, the company said.

To contact the reporter on this story: Ronit Goodman in Tel Aviv at rgoodman9@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net